Apogee Therapeutics, Inc. Common Stock (APGE) Operating Income 2022–TTM

Name: Apogee Therapeutics, Inc. Common Stock (APGE) operating income history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Apogee Therapeutics, Inc. Common Stock annual operating income for fiscal TTM was -$305 million, a decrease of 6.6% from -$286 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

APGE Annual Operating Income

Operating Income (annual)	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Income (EBIT)	($305M)	($286M)	($217M)	($93M)	($31M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

APGE Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Operating Income (EBIT)	($92M)	($83M)	($78M)	($71M)	($73M)	($63M)	($76M)	($59M)	($44M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

BMRN Operating Income — Biomarin Pharmaceutical Inc
MDGL Operating Income — Madrigal Pharmaceuticals Inc
CORT Operating Income — Corcept Therapeutics Incorporated
AXSM Operating Income — Axsome Therapeutics Inc
KRYS Operating Income — Krystal Biotech Inc
KYMR Operating Income — Kymera Therapeutics Inc

More APGE metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All APGE financial statements → Interactive APGE charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.